Core Insights - Vivoryon Therapeutics N.V. presented new data analyses from its varoglutamstat Phase 2 program at the World Congress of Nephrology, highlighting the potential of glutaminyl cyclases as targets in diabetic kidney disease (DKD) [1][2] Group 1: Company Developments - The analyses showed that varoglutamstat can significantly improve kidney function in diabetic patients, with consistent results from two independent Phase 2 studies, VIVIAD and VIVA-MIND [3] - The effect of varoglutamstat on estimated glomerular filtration rate (eGFR) was notably greater in elderly participants with diabetes compared to those without diabetes [3] - In participants with diabetes and lower baseline eGFR (mean 60 mL/min/1.73m), the effect size was comparable or higher than in the overall diabetic population [3] Group 2: Research Findings - Data from a DKD mouse model indicated significant improvements in inflammation, glomerulosclerosis, and kidney function, supporting the validity of targeting glutaminyl cyclases [3] - The results contribute to the growing evidence that inhibiting glutaminyl cyclases can address the underlying inflammatory and fibrotic changes in DKD, reinforcing the development of varoglutamstat for patients with diabetes and advanced chronic kidney disease (CKD) stages [3] Group 3: Presentation Details - The presentation at the World Congress of Nephrology took place on March 28, 2026, at 5:00 pm JST, with the poster titled "Translational Validation of Glutaminyl-Cyclases as Promising New Target for Treatment of DKD" [4] - The presenter was Christine Wenzkowski, PhD, VP of Business Development at Vivoryon [4] Group 4: Company Overview - Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for inflammatory and fibrotic disorders of the kidney, aiming to improve patient outcomes through modulation of pathologically relevant proteins [4] - The company's lead program, varoglutamstat, is a first-in-class orally available QPCT/L inhibitor being evaluated for the treatment of diabetic kidney disease [4]